Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D08GJH
|
||||
| Former ID |
DCL000727
|
||||
| Drug Name |
Blonanserin
|
||||
| Synonyms |
Lonasen; Blonanserin [INN]; AD 5423; AD-5423; Blonanserin (JAN/INN); 2-(4-Ethyl-1-piperazinyl)-4-(4-fluorophenyl)-5,6,7,8,9,10-hexahydrocycloocta(b)pyridine; 2-(4-Ethyl-1-piperazinyl)-4-(p-fluorophenyl)-5,6,7,8,9,10-hexahydrocycloocta(b)pyridine; 2-(4-ethylpiperazin-1-yl)-4-(4-fluorophenyl)-5,6,7,8,9,10-hexahydrocycloocta[b]pyridine
|
||||
| Drug Type |
Small molecular drug
|
||||
| Company |
Dainippon
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C23H30FN3
|
||||
| InChI |
InChI=1S/C23H30FN3/c1-2-26-13-15-27(16-14-26)23-17-21(18-9-11-19(24)12-10-18)20-7-5-3-4-6-8-22(20)25-23/h9-12,17H,2-8,13-16H2,1H3
|
||||
| InChIKey |
XVGOZDAJGBALKS-UHFFFAOYSA-N
|
||||
| CAS Number |
CAS 132810-10-7
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID |
7848239, 10241370, 12014539, 14755159, 29305337, 47731227, 48329041, 49958772, 50834549, 57341408, 85210029, 92718895, 93309642, 99299305, 103443179, 104047267, 104361634, 109693023, 124766870, 124772061, 124894573, 126573701, 126628409, 126651438, 126651852, 126669973, 126732498, 129746063, 134222317, 134339225, 135080521, 135916580, 137006969, 144206818, 162012053, 162172135, 162248934, 164836972, 179149822, 196106488, 196367532, 198982671, 210274889, 210280524, 211534961, 223366005, 223383025, 223657861, 226491379, 252160945
|
||||
| Target and Pathway | |||||
| Target(s) | D(2) dopamine receptor | Target Info | Antagonist | [536463] | |
| 5-hydroxytryptamine 2A receptor | Target Info | Antagonist | [536463] | ||
| PANTHER Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | ||||
| Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | |||||
| Dopamine receptor mediated signaling pathway | |||||
| Nicotine pharmacodynamics pathwayP04374:5HT2 type receptor mediated signaling pathway | |||||
| WikiPathways | Hypothetical Network for Drug Addiction | ||||
| Monoamine GPCRs | |||||
| GPCRs, Class A Rhodopsin-like | |||||
| Genes and (Common) Pathways Underlying Drug Addiction | |||||
| GPCR ligand binding | |||||
| GPCR downstream signaling | |||||
| Nicotine Activity on Dopaminergic NeuronsWP733:Serotonin Receptor 2 and STAT3 Signaling | |||||
| Serotonin Receptor 2 and ELK-SRF/GATA4 signaling | |||||
| SIDS Susceptibility Pathways | |||||
| Gastrin-CREB signalling pathway via PKC and MAPK | |||||
| GPCRs, Other | |||||
| References | |||||
| Ref 536463 | The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22. Epub 2007 Jul 31. | ||||
| Ref 542649 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7670). | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.